mycophenolate mofetil

Azathioprine failure ( 2
for treatment failure, 0.44; 95% confidence interval [CI], 0.25
to 0.77; p=0.003) treatment failure
16.4% mycophenolate mofetil ( 19
116 ) 32.4 % Azathioprine ( 36 111
)
mycophenolate mofetil


mycophenolate mofetil Azathioprine


( , 0.50; 95% CI 0.26 to 0.93;

P=0.03) mycophenolate mofetil 116

15 (12.9 %) Azathioprine 111

(Lupus nephritis )
mycophenolate mofetil Azathioprine (, 0.39;
95% CI, 0.18 to 0.87; P=0.02) 7.8% ( 9
116 ) 17.1% ( 19 111 )
mycophenolate mofetil Azathioprine
key secomdary end point definition failure
mycophenolate mofetil 42.2% ( 49 116 )
Azathioprine 56.8% ( 63 111 )
0.66; 95% CI, 0.46 to 0.97 P=0.03
21.6%(
25 116 ) 36.0% ( 40 111 )
0.56 ; 95% CI, 0.35 to 0.89; P=0.01)

mycophenolate mofetil

end-stage renal disease mycophenolate mofetil 0% (
end-stage renal disease

116 ) Azathioprine 4.5% ( 3 111 )
serum creatinine


mycophenolate mofetil 0.9% ( 1 116 )
Azathioprine 4,5% ( 5 111 )
mycophenolate mofetil
serum creatinine glomerular filtration rate
extrarenal flares

mycophenolate mofetil 6.9% ( 8 116 )
Azathioprine 6.3% ( 7 111 )
extrarenal flare

26

(23.4%)

 C3 C4
serum Azathioprine
mycophenolate mofetil

anti-double straned DNA antibiotic mycophenolate

mofetil